Lipocine Inc
LPCN3.200USD
+0.050+1.59%
Trading geöffnet （ET）Kurse um 15 Minuten verzögert
17.12MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Lipocine Inc Unternehmen
Lipocine Inc. is a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery to develop differentiated products for Central Nervous System (CNS) disorders. Its clinical development candidates include: LPCN 1154, oral brexanolone, for treatment of postpartum depression, LPCN 2101 for epilepsy, LPCN 2203 for essential tremor and LPCN 1148, a novel androgen receptor agonist prodrug for oral administration targeted for the management of symptoms associated with liver cirrhosis. It is exploring partnering opportunities for LPCN 1107, for prevention of preterm birth, LPCN1154, for rapid relief of postpartum depression, LPCN 1148, for the management of decompensated cirrhosis, and LPCN 1144, for treatment of non-cirrhotic NASH. Its product candidate, TLANDO, an oral treatment indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone.
Unternehmensinformationen
BörsenkürzelLPCN
Name des UnternehmensLipocine Inc
IPO-datumMar 21, 2014
CEODr. Mahesh V. Patel, Ph.D.
Anzahl der mitarbeiter16
WertpapierartOrdinary Share
GeschäftsjahresendeMar 21
Addresse675 S Arapeen Dr Ste 202
StadtSALT LAKE CITY
BörseNASDAQ Capital Market Consolidated
LandUnited States of America
Postleitzahl84108-1295
Telefon18019947383
Websitehttps://www.lipocine.com/
BörsenkürzelLPCN
IPO-datumMar 21, 2014
CEODr. Mahesh V. Patel, Ph.D.
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Mahesh V. Patel, Ph.D.
Dr. Mahesh V. Patel, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
109.05K
+1.52%
Mr. John W. Higuchi
Mr. John W. Higuchi
Director
Director
40.80K
--
Dr. Nachiappan Chidambaram, Ph.D.
Dr. Nachiappan Chidambaram, Ph.D.
Senior Vice President - Research and Development
Senior Vice President - Research and Development
4.41K
+11.54%
Ms. Krista Fogarty
Ms. Krista Fogarty
Principal Accounting Officer, Corporate Controller
Principal Accounting Officer, Corporate Controller
1.07K
+44.84%
Dr. Richard Dana Ono, Ph.D.
Dr. Richard Dana Ono, Ph.D.
Independent Director
Independent Director
831.00
--
Mr. Jeffrey A. (Jeff) Fink
Mr. Jeffrey A. (Jeff) Fink
Independent Director
Independent Director
386.00
--
Dr. Jill M. Jene, Ph.D.
Dr. Jill M. Jene, Ph.D.
Independent Director
Independent Director
--
--
Mr. Spyros Papapetropoulos, M.D., Ph.D.
Mr. Spyros Papapetropoulos, M.D., Ph.D.
Lead Independent Chairman of the Board
Lead Independent Chairman of the Board
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Mahesh V. Patel, Ph.D.
Dr. Mahesh V. Patel, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
109.05K
+1.52%
Mr. John W. Higuchi
Mr. John W. Higuchi
Director
Director
40.80K
--
Dr. Nachiappan Chidambaram, Ph.D.
Dr. Nachiappan Chidambaram, Ph.D.
Senior Vice President - Research and Development
Senior Vice President - Research and Development
4.41K
+11.54%
Ms. Krista Fogarty
Ms. Krista Fogarty
Principal Accounting Officer, Corporate Controller
Principal Accounting Officer, Corporate Controller
1.07K
+44.84%
Dr. Richard Dana Ono, Ph.D.
Dr. Richard Dana Ono, Ph.D.
Independent Director
Independent Director
831.00
--
Mr. Jeffrey A. (Jeff) Fink
Mr. Jeffrey A. (Jeff) Fink
Independent Director
Independent Director
386.00
--
Umsatzaufteilung
Keine Daten
Keine Daten
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionärsstatistik
Aktualisiert: Fri, May 16
Aktualisiert: Fri, May 16
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
The Vanguard Group, Inc.
4.23%
Patel (Mahesh V)
2.04%
BlackRock Institutional Trust Company, N.A.
1.67%
Geode Capital Management, L.L.C.
1.10%
Higuchi (John W)
0.76%
Other
90.20%
Aktionäre
Aktionäre
Anteil
The Vanguard Group, Inc.
4.23%
Patel (Mahesh V)
2.04%
BlackRock Institutional Trust Company, N.A.
1.67%
Geode Capital Management, L.L.C.
1.10%
Higuchi (John W)
0.76%
Other
90.20%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor
6.79%
Individual Investor
2.95%
Investment Advisor/Hedge Fund
2.16%
Hedge Fund
0.72%
Research Firm
0.05%
Other
87.32%
Institutionelle Beteiligung
Aktualisiert: Tue, Jul 1
Aktualisiert: Tue, Jul 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q2
44
678.23K
12.68%
-42.35K
2025Q1
65
678.55K
12.68%
-110.89K
2024Q4
72
645.33K
12.07%
-219.30K
2024Q3
75
703.77K
13.16%
-136.61K
2024Q2
79
690.86K
12.92%
-132.01K
2024Q1
82
639.82K
12.02%
-214.82K
2023Q4
86
649.80K
12.29%
-222.39K
2023Q3
91
667.07K
12.61%
-176.35K
2023Q2
93
641.50K
12.32%
-239.33K
2023Q1
97
745.08K
14.31%
-142.00K
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
The Vanguard Group, Inc.
226.28K
4.23%
+4.82K
+2.18%
Mar 31, 2025
Patel (Mahesh V)
109.05K
2.04%
+1.63K
+1.52%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
89.27K
1.67%
--
--
Mar 31, 2025
Geode Capital Management, L.L.C.
58.83K
1.1%
+1.37K
+2.38%
Mar 31, 2025
Higuchi (John W)
40.80K
0.76%
--
--
Mar 31, 2025
Susquehanna International Group, LLP
38.98K
0.73%
+13.97K
+55.89%
Mar 31, 2025
Renaissance Technologies LLC
37.51K
0.7%
+1.48K
+4.10%
Mar 31, 2025
Dimensional Fund Advisors, L.P.
24.93K
0.47%
+4.42K
+21.54%
Mar 31, 2025
State Street Global Advisors (US)
18.63K
0.35%
--
--
Mar 31, 2025
Northern Trust Investments, Inc.
13.16K
0.25%
--
--
Mar 31, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sat, Aug 2
Aktualisiert: Sat, Aug 2
Name
Anteil
iShares Core S&P Total U.S. Stock Market ETF
0%
DFA Dimensional US Sustainability Core 1 ETF
0%
Dimensional US Core Equity 1 ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
Anteil0%
DFA Dimensional US Sustainability Core 1 ETF
Anteil0%
Dimensional US Core Equity 1 ETF
Anteil0%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
May 11, 2023
Merger
17<1
May 11, 2023
Merger
17<1
May 11, 2023
Merger
17<1
May 11, 2023
Merger
17<1
Datum
Art
Verhältnis
May 11, 2023
Merger
17<1
May 11, 2023
Merger
17<1
May 11, 2023
Merger
17<1
May 11, 2023
Merger
17<1
